Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

News Conference News AHA 2025

Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN

Michael O'Riordan

November 08, 2025

Long-term Mortality After TAVI Lower With DOACs vs VKAs

News Conference News NY Valves 2024

Long-term Mortality After TAVI Lower With DOACs vs VKAs

June 06, 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

News Conference News THT 2024

Small Study Hints at Apixaban’s Potential in LVAD-Treated Patients

Michael O'Riordan

March 07, 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

News Conference News ISC 2024

Speedier Anticoagulation Reversal Tied to Better ICH Outcomes

February 15, 2024

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

News Conference News ESC 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

August 30, 2023

ARCADIA: Apixaban No Help for ESUS Patients With Atrial Cardiopathy

News Conference News ESOC 2023

ARCADIA: Apixaban No Help for ESUS Patients With Atrial Cardiopathy

May 25, 2023

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

News Conference News ESC 2022

Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke

August 28, 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

News Conference News ACC 2022

ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI

April 05, 2022

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

News Conference News ACC 2020

Caravaggio Backs Apixaban for Prevention of VTE Recurrence in Cancer Patients

April 01, 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

News Conference News ACC 2020

Low Mortality Rates Seen With Andexanet Alfa for Factor Xa-Related Bleeds

March 25, 2020

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

News Conference News AHA 2019

Some A-fib Patients May Need a Bit More Aspirin After PCI: AUGUSTUS

November 20, 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

News Conference News ISC 2019

Final ANNEXA-4 Results Published, Confirm Rapid Andexanet Alfa Effects

February 13, 2019

ACC 2018, Day Three: Gout, Hypertension, and Diabetes Dominate Opening Late Breaker

News Conference News ACC 2018

ACC 2018, Day Three: Gout, Hypertension, Diabetes, PFO Closure, DAPT, NOAC Reversal, and More

March 12, 2018

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

News Conference News VIVA 2017

Apixaban May Be Better Choice Than Rivaroxaban for DVT Patients

September 11, 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

News Conference News ACC 2017

Rivaroxaban Bests Aspirin for Preventing Recurrence of VTE: EINSTEIN CHOICE

March 18, 2017

NOAC-Related Intracranial Hemorrhages May Not Be as Bad as Those Stemming From Warfarin

News Conference News ISC 2017

NOAC-Related Intracranial Hemorrhages May Not Be as Bad as Those Stemming From Warfarin

March 01, 2017

News Conference News ESC 2016

Reversal Agent for Factor Xa Inhibitors Rapidly Reduces Anticoagulant Effects: ANNEXA-4

August 31, 2016

News Conference News ESC 2016

NOACs as Effective as Warfarin for Reducing Stroke, but Apixaban and Dabigatran May Carry Lower Bleeding Risk: Registry

Michael O'Riordan

August 28, 2016

News Conference News

RUBY-1: Yet Another Novel Anticoagulant Tested in ACS Patients on Antiplatelets

August 31, 2011

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.